Financial Performance - The company's net profit attributable to shareholders is expected to be between 359.95 million and 375.07 million CNY, representing a year-on-year growth of 19% to 24%[3] - The net profit attributable to shareholders after deducting non-recurring gains and losses is projected to be between 358.55 million and 373.12 million CNY, indicating a growth of 23% to 28% compared to the previous year[3] Brand and Market Strategy - The core operating brands, including Diqiao, Hale, and Nutshuma, have shown steady revenue growth, enhancing the company's core competitiveness and operational performance[4] - The company has focused on brand operation and product differentiation to meet patient needs during the reporting period[4] - Continuous efforts in market promotion have increased the market share of core brands in hospitals, pharmacies, and online platforms[4]
百洋医药(301015) - 2024 Q2 - 季度业绩预告